BioCentury This WeekWUSA9
About The Show Meet The Team Program Archive Become a Sponsor
UPDATE FLASH PLAYER AND EXPERIENCE THE NEW BCTV SHOW GUIDE

Mobile Banner Image


      HOME     ABOUT BIOCENTURY     WHY BCTV?     PRESS RELEASES    FREE CONTENT    LINK TO BCTV    CONTACT US   
Advertisement



BIOCENTURY EXTRA LATEST HEADLINES


   TOP STORY

Merck buying Sigma-Aldrich for $17B

Merck KGaA (Xetra:MRK) will acquire Sigma-Aldrich Corp. (NASDAQ:SIAL) for about $17 billion in cash. Merck will pay $140 per share, a 37% premium to Sigma-Aldrich's Friday close of $102.37, before the news was announced Monday. Merck will finance the deal with cash, bank loans and bonds. more >>

   COMPANY NEWS

Avalon, GSK launch two newcos

Avalon Ventures and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) launched Silarus Therapeutics Inc. (San Diego, Calif.) and Thyritope Biosciences Inc. (San Diego, Calif.). Each may receive up to $10 million in series A financing, comprising $3 million in equity investment from Avalon and up to $7 million in R&D support from GSK. The companies will be housed at Avalon's COI Pharmaceuticals incubator, and funded on a quarterly basis. more >>

Pfizer, Circle in macrocycle deals

Circle Pharma Inc. (San Francisco, Calif.) announced two collaborations with Pfizer Inc. (NYSE:PFE) to design and develop macrocyclic peptides against two undisclosed Pfizer targets. Circle will develop the peptides using computational design algorithms, and Pfizer will test them in undisclosed indications. more >>

Auxilium board affirms QLT deal

The board of Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL) unanimously reaffirmed its proposed merger agreement with ophthalmic play QLT Inc. (NASDAQ:QLTI; TSX:QLT) after reviewing an unsolicited bid from Endo International plc (NASDAQ:ENDP; TSX:ENL). more >>

FDA grants expanded access for Tekmira's TKM-Ebola

Tekmira Pharmaceuticals Corp. (TSX:TKM; NASDAQ:TKMR) jumped $3.45 (17%) to $23.61 in New York and C$3.39 (15%) to C$26.01 in Toronto on Monday after FDA granted expanded access use of TKM-Ebola in patients with confirmed or suspected Ebola infections. Tekmira also said Health Canada established a similar framework. more >>

Japan approves Eylea for myopic CMV

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said Japan's Ministry of Health approved Eylea aflibercept to treat myopic choroidal neovascularization (myopic CNV), the second leading cause of blindness in Japan. The Bayer Yakuhin Ltd. subsidiary of Bayer AG (Xetra:BAYN) holds ex-U.S. rights to Eylea from Regeneron. The drug is a human fusion protein that binds all forms of VEGF-A and placental growth factor (PGF; PlGF). more >>

   CLINICAL NEWS

Threshold down on Phase III data delay

Threshold Pharmaceuticals Inc. (NASDAQ:THLD) fell $0.50 (11%) to $3.97 on Monday after saying it expects delayed data from its Phase III trial of TH-302 to treat unresectable or metastatic soft tissue sarcoma (STS). more >>

   FINANCIAL NEWS

Tracon raises $27M in B round

Tracon Pharmaceuticals Inc. (San Diego, Calif.) raised $27 million in a series B round led by New Enterprise Associates. Additional new investors included BioMed Ventures and an undisclosed institutional investor. Existing investors JAFCO; Nextech Invest; Brookline Investments; Arcus Ventures; and BHP also participated. more >>

Avanir and Vital Therapies propose follow-ons

Vital Therapies Inc. (NASDAQ:VTL) said in an SEC filing on Monday that it plans to raise $46 million in a follow-on underwritten by BofA Merrill Lynch; William Blair; Canaccord Genuity; and SunTrust Robinson Humphrey. Vital closed down $1.84 to $18.27 on the day. more >>

Tesaro planning $165M note deal

Oncology play Tesaro Inc. (NASDAQ:TSRO) proposed late Monday to raise $165 million through the sale of senior unsecured convertible notes through Citigroup; Deutsche Bank Securities; Leerink; Baird; and BMO Capital Markets. The notes mature in October 2021. more >>

   POLITICS & POLICY

FDA meeting on abuse-deterrent opioids

FDA will hold a public meeting in Silver Spring, Md., on Oct. 30-31 to discuss the development, assessment, and regulation of abuse-deterrent opioid medications. The meeting will focus on scientific and technical issues related to the development and in vitro assessment of such drugs, and FDA's approach to the benefit-risk assessment of all opioid treatments. more >>

Dems propose increased NIH funding

Reps. Rosa DeLauro (D-Conn.) and Brian Higgins (D-N.Y.) introduced a bill in the U.S. House of Representatives that would lift the cap on NIH funding due to sequestration. more >>

Advertisement

BIOCENTURY, THE BERNSTEIN REPORT ON BIOBUSINESS

BIOCENTURY, THE BERNSTEIN REPORT ON BIOBUSINESS
COVER STORY

Weighing in on obesity

The newest obesity drugs will have the weight of pharma companies behind them in the key cardiometabolic markets required for success.

Pandora's CVOT

The Contrave case highlights the challenges of running a single CV outcomes trial to satisfy FDA while protecting the data.

PRODUCT DISCOVERY & DEVELOPMENT

Glenmark's new cancer BEAT

Glenmark's BEAT platform generates bispecific antibodies that sidestep hurdles faced by other technologies.

EMERGING COMPANY PROFILE

Emulate: Organs on chips

Emulate, spun out of the Wyss Institute for Biologically Inspired Engineering, sees personalized medicine uses for its organs-on-chips.

Zai: Capitalizing on China

Zai is looking to in-license and develop novel compounds that target diseases prevalent in China.

FINANCE

Scholar Rock's niche

Scholar Rock raises $20 million for new class of drugs targeting growth factors

Polar (large) caps

Polar launches fund to capitalize on large caps in healthcare consolidation

Academic ventures

California following footsteps of Texas with VC fund to invest in UC research

Caught short

Why RA Capital paid fine after shorting stocks

User Agreement | Terms of Use | Privacy Policy | Your California Privacy Rights | Use of Images

Advertisement